Sophie Vo
3 min
To add to all the chatter about AI, let's talk about AI as a medical device.
Last...
COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located. This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.
Today we release the latest in our series, focusing on Market Access, please click on the link below to view this tracker:
Other trackers available in this series:
- COVID-19: Legislation Tracker for Medical Devices, read here
- COVID-19: Legislation Tracker for Clinical Trials, read here
- COVID-19: Legislation Tracker for Public Procurement, read here
- COVID-19: Legislation Tracker for State Use/Compulsory Licensing, read here
